Johnson & Johnson reported resilient sales growth and exceeded earnings expectations, driven by promising results in its Innovative Medicine segment and potential growth from its MedTech OTTAVA system. However, softness in profitability and ongoing regulatory risks raise caution. Despite operational strength, the stock's high forward P/E and PEG ratios make it less attractive for new investors. The analyst downgraded the stock to Hold, recommending current investors maintain positions while being wary of mixed fundamentals and regulatory challenges.
Following the mixed signals from Johnson & Johnson's latest earnings and regulatory concerns, the stock is experiencing a notable drop on Pluang. As of Oct 14, 2026 03:41 WIB, JNJ shares trade at USD 248.96, down 5.60% for the day. The stock holds a market cap of $635.56 billion and a dividend yield of 2.03%, with a typical hold time of 129 days among Pluang investors.
Johnson & Johnson reported a 6% revenue increase to $25.4 billion in Q3 2026, but earnings per share (EPS) declined 7.5% year-on-year, causing the stock to fall 5%. The company set aside $5.5 billion to resolve talc litigation, aiming for 95% plainti...
Johnson & Johnson reported third-quarter 2026 earnings per share of $2.59, surpassing analyst estimates of $2.52, with total revenue of $25.40 billion slightly above expectations. The company saw robust growth in its pharmaceutical segment, which off...
Johnson & Johnson's stock dropped 5% after reporting a 95.9% fall in net earnings caused by one-time charges including talc litigation costs, despite raising its full-year sales and adjusted earnings outlook. The company's Innovative Medicine divisio...
Johnson & Johnson increased its 2026 sales forecast to $101.2 billion and raised adjusted EPS guidance to $11.10 after reporting a 6% operational sales growth in Q3. The growth was driven by strong performance in its Innovative Medicine division, esp...
Johnson & Johnson's TREMFYA (guselkumab) demonstrated consistent combined fistula remission rates of up to 28% at Week 24 in adults with Crohn's disease and perianal fistula, outperforming placebo at 10%. New Phase 3 subgroup analyses from the FUZION...
